Rick Ascroft

Stories

FDA approves ILUMYA for psoriatic arthritis, adding an in-office IL-23 option

Leads US commercial launch of ILUMYA for psoriatic arthritis

On October 30, 2026, the Food and Drug Administration approved ILUMYA for adults with active psoriatic arthritis. The drug, tildrakizumab, had been cleared since 2018 only for plaque psoriasis, a skin condition.

Updated 1 hour ago